GlassScriptPhysician profile
Aimee M Tegtmeier
NPI 1497042972
$649.69
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $119 · 2021: $18.84 · 2022: $14.53 · 2023: $70.37 · 2024: $30.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $129.20 | 2019-2020 | |
| Novo Nordisk INC | $65.81 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $57.51 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $55.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.05 | 2019 | |
| Pfizer INC. | $44.16 | 2019-2022 | |
| Sanofi Pasteur INC. | $33.93 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.51 | 2019 | |
| Allergan, INC. | $29.09 | 2020 | |
| Dexcom, INC. | $28.36 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $26.98 | 2019-2020 | |
| Abbott Laboratories | $19.00 | 2023 | Freestyle Libre 3 |
| Journey Medical Corporation | $18.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.25 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $16.20 | 2019 | |
| Amgen INC. | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Tegtmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.